BAUDETTE, Minn., Jan. 14, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg. The ...

Janssen, L.P.'s INVEGA Approved By FDA As New Treatment For Schizophrenia TITUSVILLE, N.J., Dec. 20 /PRNewswire/ -- First Oral Extended Release Medication to Treat Schizophrenia. The U.S. Food and ...

Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, the generic version of Janssen's Invega®. Mylan received final approval ...

Paliperidone Extended-Release Tablets is an atypical antipsychotic agent indicated for the treatment of schizophrenia and schizoaffective disorder. Southeastern Grocer's president and CEO and C&S ...

Amneal is introducing its generic Invega (paliperidone) extended-release tablets. The drug will be available in dosage strengths of 1.5 mg, 3 mg, 6 mg and 9 mg. Janssen is the brand manufacturer of ...

BRIDGEWATER, NJ.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has launched its generic version of Invega ® (paliperidone) extended-release tablets, 1.5 mg, 3 mg ...

Philadelphia, PA, December 13, 2007 – Schizophrenia is one of the most debilitating of the major psychiatric disorders, and is also one of the most difficult to treat. Although numerous antipsychotic ...

PRINCETON, N.J., July 28, 2024 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today ...

BRIDGEWATER, NJ.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has launched its generic version of Invega® (paliperidone) extended-release tablets, 1.5 mg, 3 mg ...